Glioblastomas are the most common primary brain tumors in adults. These tumors exhibit a high degree of vascularization, and malignant progression from astrocytoma to glioblastoma is often accompanied by increased angiogenesis and the upregulation of vascular endothelial growth factor and its receptors. In this study, we investigated the in vivo antiangiogenic and antitumor effects of brain-specific angiogenesis inhibitor 1 (BAI1) using human glioblastoma cell lines. Glioblastoma cells were transduced with an adenoviral vector encoding BAI1 (AdBAI1), and Northern and Western blot analyses, respectively, demonstrated BAI1 mRNA and protein expression in the transduced tumor cells. Using an in vivo neovascularization assay, we found that angiogenesis surrounding AdBAI1-transduced glioblastoma cells transplanted into transparent skinfold chambers of SCID mice was significantly impaired compared to control treated cells. Additionally, in vivo inoculation with AdBAI1 of established subcutaneous or intracerebral transplanted tumors significantly impaired tumor growth and promoted increased mouse survival. Morphologically, the tumors exhibited signs of impaired angiogenesis, such as extensive necrosis and reduced intratumoral vascular density. Taken together, these data strongly indicate that BAI1 may be an excellent gene therapy candidate for the treatment of brain tumors, especially human glioblastomas.
Introduction
Recent scientific advances have translated into improved treatment modalities for different malignancies, but, despite this, the prognosis for gliomas, particularly glioblastomas, remains very poor. In an effort to improve the prognosis of glioblastoma, different gene therapy approaches have been explored since 1992, 1 and preliminary studies examining the intratumoral transplantation of HSV-TK retrovirus-producing cells have met with limited success. Angiogenesis is essential for tumor growth and progression, and the disruption of normal vascular growth factor and receptor function by gene therapy holds promise for the treatment of many solid tumors. Indeed, preliminary data from several experimental models support this hypothesis. [2] [3] [4] BAI1 (brain-specific angiogenesis inhibitor 1), a p53-inducible gene, is a member of the secretin receptor family 5 and appears to play a role in the bystander effect induced by wild-type p53 gene transduction on adjacent tumor cells. 6 Expression of BAI1 was absent or significantly reduced in eight of nine glioblastoma cell lines examined. Additionally, Kaur et al. found no BAI1 expression in 13 of 18 human glioblastomas, whereas BAI1 was expressed in adjacent non-neoplastic brain tissue. They did not examine the role of p53 in regulating BAI1 mRNA expression in glioma cells, however. 8 Interestingly, a recombinant protein containing the TSP-type 1 repeats of BAI1 inhibited the in vivo neovascularization induced by bFGF on rat corneas. Taken together, these results suggest that BAI1 might play a significant role in the inhibition of angiogenesis downstream of p53. 7 Furthermore, recent evidence has implicated BAI1 in the neovascularization of other malignancies including colorectal cancer, pulmonary adenocarcinoma, and gastric cancer. [9] [10] [11] However, the mechanism of action of BAI1 as well as a direct antitumor effect in vivo has yet to be demonstrated. Retroviral vectors were the first delivery systems used in clinical studies of the efficacy of gene therapy. This approach is limited by the inability of retroviruses to transduce nondividing cells. 1 Thus, more recent studies have used adenoviral delivery systems that are able to efficiently transfect both dividing and nondividing cells. 6, 12, 13 In this study, we used an adenoviral delivery system to study the ability of BAI1 to inhibit tumor growth in mice transplanted with human glioblastoma cells both subcutaneously and intracerebrally.
Materials and methods

Construction of recombinant adenovirus
Construction of recombinant adenoviral vectors was conducted as previously reported. 20 Briefly, we used the COS-TPC method to construct recombinant adenoviruses carrying human BAI1 cDNA or p53 cDNA. Human BAI1 cDNA or p53 cDNA were inserted into the cassette cosmid pAdexlw, an 11-kb charomid vector bearing an adenovirus 5 genome with deletions of E1 and E3. The recombinant adenovirus promoted by the CAG promoter, AdeBAI1 and Adep53, was generated by in vitro homologous recombination in 293 cells between the cosmid cassette and NsiI-digested adenovirus DNA, tagged with viral terminal proteins. Recombinant adenovirus carrying a LacZ expression unit was controlled by the CAG promoter (AxCALacZ). 21 The adenovirus used in the following experiments was further purified and concentrated by CsCl gradient centrifugation followed by dialysis against phosphate-buffered saline (PBS)-10% glycerol buffer. Titration of recombinant adenovirus was performed by 50% tissue culture infectious dose (TCID50). Lack of contamination by replication-competent adenovirus (RCA) was confirmed by the inability to amplify a fragment of the E1B region by polymerase chain reaction (PCR). PCR primers used were 5 0 -ATG AGA CAT ATT ATC TGC CAC GGA GGT GTT ATT AC-3 0 and 3 0 -A CCG AAA GGT GGG TCA CTG CTG CTC CTA CTT CTC C-5 0 . All viruses were purified and expanded in 293 cells by the standard technique. Each viral inoculum was purified by a CsCl step gradient, followed by a CsCl equilibrium gradient. The final viral band was diluted 1:1 with sterile glycerol and stored at À801C. Viral concentration was determined by measuring the optical density at 260 nm. The multiplicity of infection (MOI) was calculated on the basis of the ratio of functional virus, using 293 cells, as reported previously. 20 In vitro transduction by recombinant Ad vectors During the exponential growth phase, glioma cell lines were harvested by a brief treatment with 0.25%. trypsin and 0.02% EDTA, and seeded onto new culture plates with fresh medium containing 10% FCS. After 24 h, different dilutions (MOI ¼ 0, 100) of recombinant Ad vector (Ad-vector, Ad-BAI1) were added to the cell monolayers and distributed evenly by gentle swirling. After 2 h, cells were washed and cultured in fresh medium at 371C in 5% CO 2 .
Total RNA extraction and semiquantitative RT-PCR Total RNA was extracted from U373MG cell pellets as well as intracerebral tumors inoculated with U87MG cells using Trizol reagent. RT-PCR was used to detect the presence of mRNA. In total, 30 cycles of PCR were performed with primers derived from the BAI1 (5
0 ) (941C 30 s, 551C 30 s, 721C 2 min) to yield a product of 414 and 344 bp, respectively. RT-PCR was performed using an RNA PCR kit (AMV) (Takara Shuzo, Kyoto, Japan) according to the manufacturer's instructions. Spectrodensitometry was used to measure the expression of BAI1 and b-actin.
Animals
The experiments were performed using SCID mice (SPF/ VAF 4 weeks old, C.B-17/Icr. Crj-SCID, 25-30 g body weight) purchased from Nippon Charles River Co. (Yokohama, Japan), bred and maintained in a specific germ-free environment in our laboratory. During the surgical procedure and microscopic observation, amounts of the antimicrobial reagents added per one liter drinking water were: oxytetracycline, 0.3 g; ampicillin, 0.3 g; cloxacillin, 0.2 g; and potassium sorbate, 1.35 g. The pH was adjusted to 2.5 with HCl. 11 All experiments were performed according to guidelines of the Institute of Medical Science, The University of Tokyo, including the intraperitoneal administration of sodium pentobarbital (Nembutal, 50 mg/kg) for general anesthesia.
Cell lines
Five glioblastoma cell lines were used in this study. YKG1 was purchased from HSRRB (Tokyo); U87MG, U373MG, SW1783, and DBTRG05MG were purchased from American Type Culture Collection (ATCC) (Mannasas, VA). YKG1, U87MG, U373MG, and DBTRG05MG were maintained in Eagle's MEM medium supplemented with nonessential amino acids, sodium pyruvate (1 mM), and Eagle's BSS (10% fetal bovine serum, 2 mM L-glutamine, streptomycin (100 mg/ ml), and penicillin (100 U/ml)). SW1783 was maintained in Leibovitz's L-15 medium supplemented with 10% fetal bovine serum, as recommended by the ATCC.
Northern blot analysis
For experiments designed to detect mRNA, glioblastoma tumor cells were grown to confluence in six-well plates and transduced with 5 Â 10 8 PFU/ml AdBAI1 or other adenoviral vectors. Cells were harvested at the indicated times, and RNA was extracted and subjected to Northern blot analysis. RNA was extracted from cultured cells with Trizol reagent (Life Technologies, Rockville, MD) according to the manufacturer's instructions. RNA from tumor cell lines and tumor tissue was separated on formaldehyde-agarose gels and blotted onto nitrocellulose filters (Micron Separations, Westboro, MA). BAI1 mRNA was detected by hybridization of membranes with 32 P-labeled BAI1 cDNA as previously reported. 8 To check the quality of loaded mRNA, blots were also hybridized with a 32 P-labeled b-actin cDNA. The cDNA probes were labeled with [ 32 P]dCTP (Amersham life Sciences) by the random-primer method to a specific activity of 42 Â 10 9 dpm/mg. Blots were hybridized in QuickHyb solution (Stratagene, La Jolla, CA) at 681C for 1 h, followed by washing in 0.1 Â SSC, 0.1% SDS at 651C and autoradiography (1 Â SSC is 0.15 M NaCl plus 0.015 M sodium citrate). The radioactivity of each band was quantified with a Fuji Bas 1000 bioimaging analyzer and MacBas software.
Western blot analysis
Western blot analysis was performed following standard methods. Briefly, AdBAI1-transduced or nontransduced glioblastoma cells were homogenized, and the centrifuged supernatants were electrophoresed in 7% acrylamide gels and blotted onto nitrocellulose membranes. The membranes were blocked with 3% bovine serum albumin (BSA) in PBS and incubated for 2 h with rabbit antihuman BAI1 serum (provided by Dr Tokino) diluted 1:2000 in 1% BSA, 0.05% Tween-20 in PBS. After washing several times, the membranes were incubated 1 h with horseradish peroxidase-labeled goat anti-rabbit IgG (Jackson Immuno Research Laboratories, Inc.) diluted to 1:5000 in 1% BSA, 0.05% Tween-20 in PBS. For detection, the enhanced chemiluminescence method (ECL; Amersham, Arlington Heights, IL) was used and the membranes were exposed to Fuji (Tokyo, Japan) RX-U film for 10-30 s.
Dorsal skinfold transparent chamber
Dorsal skinfold transparent chamber analysis was performed as reported previously. 22 Briefly, titanium frames were implanted into mice so as to sandwich extended double layers of skin perpendicularly to the animal's back. One circular (15 mm diameter) layer of skin was completely removed, and the remaining layer composed of epidermis, subcutaneous tissue, and muscle was covered with a coverslip incorporated into one of the frames. Using stainless steel nuts as spacers, animals tolerated to the chambers and showed no signs of discomfort. In particular, no differences in sleeping and feeding habits were observed. The chamber implantation time was about 20 min per mouse. For intravital microscopy, unanesthetized animals were immobilized in polyethylene tubes attached to the microscope stage. Images were captured with an intensified CCD camera (TEC-470, Optronics Co., Chelmsford, MA) attached to the microscope and serially connected to a TV monitor (BM-1400S Vitor Co., Tokyo, Japan) and recorded on an S-VHS video tape recorder (HR-X1, Video Co., Tokyo, Japan). In this study, observations were performed at days 0, 3, 6, 9, and 12 after tumor inoculation.
Histology
Specimens were fixed in phospho-lysine-paraformaldehyde solution at 41C overnight, embedded in TissueTek O.C.T. compound (Sakura Finetechnical Co., Ltd, Tokyo, Japan) and stored at À801C. Sections of 5 mm were cut for immunohistochemical staining. Purified anti-BAI1 antiserum diluted 1:300 in 1% BSA in PBS was used for staining. Expression of von Willebrand factor was detected using rabbit polyclonal antiserum (Dako, Tokyo, Japan). Following the standard protocol supplied by Dako, tissue sections were incubated with 3% hydrogen peroxide in distilled water (DDW) for 5 min, rinsed with DDW, and placed in Tris-buffered saline (TBS) for 5 min. After rinsing, the specimens were covered with 2-3 drops of DAKO EPOS Anti-von Willebrand Factor/HRP (one drop equals to 50 ml), and incubated for 60 min at room temperature. As a negative control, DAKO EPOS Negative Control (code No.U 0951) antibody was used following the manufacturer's protocol. The specimens were then rinsed in TBS for 5 min, incubated with DAB for 5-15 min, rinsed again with DDW, counter stained, and mounted on coverslips. The vascular densities were obtained by counting the vessels under the microscope; we counted four fields per sample.
X-gal staining Cells were spun downfixed with a methanol-formaldehyde mixture for 1 h, incubated in 0.2% glutaraldehyde in PBS for 30 min, stained for b-galactosidase activity for 4 h at 371C (by incubating in PBS with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal, 400 mg/ml), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl 2 ), and lightly counter stained with hematoxylin eosin. Sections were briefly immersed in 4% paraformaldehyde, washed extensively with PBS, and immersed in a solution containing 1 mg/ml X-gal, 2 mM MgCl 2 , 5 mM K 3 Fe(CN) 6 , and 5 mM K 4 Fe(CN) 6 in PBS, overnight at 371C. Sections were rinsed in PBS and counter stained with hematoxylin/eosin and mounted on coverslips in PBS/glycerol for microscopic observation.
In vivo glioblastoma therapy model using SCID mice To examine whether the combination of Adep53 and AdeBAI1 had a synergistic antitumor effect, a half maximal effective dose of Adep53 and AdeBAI1 individually were established. The U373MG cells were transduced at the same dosage with Adep53, or AdeBAI1, or combination of Adep53 and AdeBAI1, or AdeMock, or culture medium (WT) (MOI ¼ 30), transplanted into mice, and the tumor size and mice survival were observed.
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To observe the therapeutic efficacy of intratumoral injection of AdBAI1, 1 Â 10 7 human glioblastoma cells were implanted intradermally into the right flank of SCID mice. Tumors developed up to 5-10 and 25 mm in diameter at days 14 and 56, respectively, after transplantation. When tumors grew to 5-10 mm in diameter, 2 Â 10 9À10 PFU in 50-100 ml volume of AdBAI1, AdLacZ, or AdV-RR5 were injected into the tumors using a 26-gauge needle. Injections were repeated every other day. The presence of a detectable tumor was confirmed by palpation, and the tumor size was recorded periodically.
Intracerebral tumor inoculation and therapy
To create an animal brain tumor model, a stereotactic injection technique was employed based primarily on the work of Martuza et al., 23 except that the injection position was modified. CD1 nu/nu athymic nude mice (6 weeks old) were placed in a stereotactic apparatus (Kopf). A burr hole was drilled 3 mm posterior and 3 mm lateral to the bregma. The U87MG cell suspension (1 Â 10 5 cells in 3 ml of HBSS) was injected stereotactically over a 10-min period using a Hamilton syringe at a depth of 3.5 mm. After 3, 6, and 9 days, animals were anesthetized again for intratumoral administration of recombinant adenoviruses. The same coordinates were used for the virus injection, except that the needle was placed 1 mm deeper than for the tumor cell injection, and the virus was injected at six points at 0.5-mm intervals; 5 Â 10 7 PFU AdBAI1 or AdMOCK (control) were injected in a volume of 0.5 ml at each of the six levels over a 15-min period. The needle was withdrawn within 20 min.
Data analysis
Experimental significance was determined by an unpaired t-test. Statistical analyses were performed on a microcomputer with the aid of the SigmaStat program (Jandel Scientific, San Rafael, CA). Data are presented as mean7s.e.m.
Results
Successful BAI1 expression in adenovirus-transduced cells
We used a recombinant adenovirus containing human BAI1 cDNA controlled by the CAG immediate early gene promoter (pAdexICAwt-BAI1, denoted AdeBAI1). The human glioblastoma cell lines SW1783, YKG1, DBTRG05MG, U87MG, and U373MG were transduced in vitro with AdeBAI1 at an MOI of 30 for 48 h. Following transduction, all cell lines expressed BAI1 at both the mRNA (Figure 1a ) and protein (Figure 1b) level, but nontransduced wild-type cells did not express BAI1 (Figure 1a, b) . When tumors were transduced with AdeBAI1 in vivo, BAI1 was clearly detected immunohistochemically, but both the mock-and AdLacZtransduced cells did not express BAI1 (Figure 2) . Thus, AdBAI1 effectively transduced glioblastoma cells both in vitro and in vivo allowing for a more detailed examination of the effect of BAI1 on tumor growth and survival.
BAI1 inhibits angiogenesis
We next transplanted wild-type, AdLacZ-, or AdBAI1-transduced U373MG cells into mice and examined the neovascularization surrounding and within the tumors after transplant. A vascular network formed over the entire tumor area in mice transplanted with wild-type or AdLacZ-transduced cells at days 1, 3, 6, 9, and 12 posttransplantation, as compared with those at day 0 (a, b, c Figure 3A ). In mice injected with DMEM or AdLacZ tumors, blood vessels infiltrated into the tumor tissue (d or e respectively in Figure 3A) . Conversely, angiogenesis was completely inhibited in the dorsal skinfold chambers of SCID mice transplanted with AdBAI1-transduced cells at day 12 post-transplantation (f in Figure 3A ). Immunohistochemical staining for von Willebrand factor revealed normal endothelia within tumors consisting of U373MG cells with or without AdLacZ transduction (16.073.2 blood vessels per Â 200 field), but tumors comprised of U373MG cells transduced with AdBAI1 stained very poorly for this endothelial marker (1.672.5 blood vessels per Â 200 frames) ( Figure 3B ). Additionally, we observed in vivo tumor formation in the mice receiving AdLacZ transduced cells but not those who received AdBAI1 transduced cells. 
BAI1 inhibits tumor growth
In total, 35 days following the injection of transduced or wild-type U373MG glioblastoma cells, the mean tumor sizes in SCID mice transplanted with wild-type or control adenoviral vector-transduced cells were significantly larger than those transplanted with tumor cells adenovirally transduced with p53, BAI1, or p53 þ BAI1. Combined transduction with AdBAI1 and AdP53 did not synergistically inhibit U373MG tumor growth compared to AdBAI1 or AdP53 alone (Figure 4) . We next examined the ability of AdBAI1 to inhibit the growth of wild-type transplanted tumors. Following tumor implantantation, SCID mice were injected intratumorally with AdLacZ, AdBAI1, or DMEM. Tumors injected with AdBAI1 regressed significantly compared to those injected with AdLacZ (*P ¼ 0.003, Figure 5 ) or DMEM (*P ¼ 0.003, Figure 5 ). These results were reproducible over two experiments.
The results discussed above clearly showed that BAI1 significantly slowed the growth of established tumors, and we next examined the survival of SCID mice following the in vivo transduction of established U373MG tumors. Mice transplanted with wild-type U373MG tumor cells followed by injection with medium or AdLacZ adenovirus survived 63711.35 and 62.4713.04 days, respectively, and the survival rate was 20% at 80 days after injection for both groups. In contrast, mice with tumors injected with AdBAI1, survived significantly longer (7776.32 days) than control mice injected with medium (P ¼ 0.005) or AdLacZ (P ¼ 0.0064), and 80% of these mice were alive at day 80 when they were sacrificed ( Figure 6 ).
Increased survival following AdBAI1 treatment of glioblastoma in intracerebrally inoculated mice
Our results clearly show that transduction of glioblastoma cells with adenovirus encoding BAI1 inhibits tumor growth and promotes animal survival when tumors are implanted outside the central nervous system. In order to determine if BAI1 has similar effects within the brain, we inoculated mice intracerebrally with U87MG and U373MG cell lines and observed the animals up to 30 days. Tumors arising after U87MG inoculation were well established and highly vascularized by day 3, but, in contrast, tumors were not established in mice inoculated with U373MG, even after 30 days. Therefore, the U87MG cell line was used for all subsequent experiments. All mice transplanted with U87MG cells followed by AdMOCK adenovirus injection were dead by day 20, while by this time, only one animal died from the AdBAI1-treated group. By day 27, five of six of the AdBAI1-treated mice were dead, but the mean survival Antiangiogenic activity to BAI1 in vivo X Kang et al time of the AdBAI1-treated mice (2674.6 days) was significantly longer than that of the AdMOCK-treated mice (17.372.3 days) (Po0.05, Figure 7 ). While all the mice developed tumors, BAI1 was expressed only in the AdBAI1-injected tumors (data not shown).
Discussion
Angiogenesis is thought to be controlled by the continuous interplay of positive and negative regulators of blood vessel formation. The recent discovery of endogenous angiogenesis inhibitors, including thrombospondin 1 (TSP1), endostatin, angiostatin, and glioma-derived angiogenesis inhibitory factor, suggested a novel and powerful treatment paradigm for inhibiting tumor growth. Hsin-I Ma et al. 14 showed that a single intramuscular injection with an adeno-associated viral (AAV) vector expressing angiostatin (a potent angiogenic inhibitor) effectively suppressed human glioma growth in the brains of nude mice, suggesting that blocking tumor neovascularization could be an effective treatment for glioblastoma. BAI1 is a 1584 amino-acid gene product containing five TSP1 repeats, and recent reports have suggested that BAI1 may play a key role regulating the vascularization of tumors. [9] [10] [11] In this study, we examined the effects of BAI1 on vascularization using the transparent chamber model, which is particularly useful for studying the early stages of angiogenesis. We introduced BAI1-transduced or nontransduced U373MG cells into a dorsal skinfold chamber of SCID mice. After 2 weeks, functional vascular networks encompassing the entire tumor area developed in animals inoculated with AdLacZ-transduced or nontransduced cells, but vascularization did not occur in animals given AdBAI1 transduced cells. These results suggest that BAI1 has a direct antiangiogenic effect on neovascularization.
In a previous study, inhibition of p53 activity in human tumors was closely correlated with reduced vascularity, suggesting that p53 may inhibit angiogenesis through an unknown mechanism.
15 BAI1 was hypothesized to be a major effector molecule in p53-induced antiangiogenesis and antitumor effects in glioblastomas. To further explore this hypothesis, we transduced U373MG cells with AdBAI1, AdP53, or both, and transplanted these cells into the flanks of SCID mice. BAI1 and p53 inhibited tumor growth to the same extent, and, interestingly, no synergy was seen when both proteins were expressed in cells simultaneously (Figure 4) . It is possible that p53 may induce BAI1, and this protein may be responsible for the effects seen in AdP53 transduced cells. Alternatively, BAI1 could affect the expression of p53 itself or other molecules within the p53 signaling pathway. Such a phenomenon was observed in another p53 combination gene therapy model. 12 Further studies, including analyses of the expression patterns of p53 related genes, are required to clarify the relationship of p53, BAI1, and the anti-angiogenesis effects seen in this study.
In order to investigate the ability of AdBAI1 to inhibit the growth of established tumors, we intradermally inoculated SCID mice with U373MG cells and subsequently intratumorally injected AdBAI1, AdMOCK, or PBS. A substantial reduction in tumor volume was only observed in mice injected with AdBAI1, and these mice survived for significantly longer than control injected mice ( Figure 5 ). It is likely that there is a direct correlation between the inhibition of tumor growth, prolonged animal survival, and inhibition of angiogenesis by BAI1. Recently, Kaur et al. 16 reported that vasculostatin, a proteolytic fragment of BAI-1, is both anti-angiogenic and inhibited tumor growth. Although we did not examine whether this proteolytic fragment was generated in our system, the BAI1 produced by transduced cells most likely mediated its antitumor effects in a paracrine manner.
Intracerebral inoculation with U87MG cells leads to tumor formation and growth. 13 We transplanted U87MG and U373MG cells into the brains of mice and found that the U87MG formed tumors much more readily than U373 cells. We have no explanation for the differential ability of these cell lines to form tumors after intracerebral inoculation, but it is clearly not due to BAI1 expression as neither cell line expressed BAI1 in vitro (Figure 1a and b) . Tumors generated after the intracerebral injection of U87MG cells had characteristics of human glioblastomas, including high vascularization and rapid growth (data not shown). Therefore, we selected U87MG cells for further experiments. Intratumoral injection of AdBAI1 inhibited the growth of tumors inoculated subcutaneously (data not shown) and intracerebrally. Additionally, the AdBAI1-treated animals survived significantly longer than control treated mice, suggesting that inhibits tumor growth in vivo within the central nervous system. After euthanasia and brain removal, however, all animals had tumors regardless of treatment. There are several possible reasons why this was the case. Not all of the tumor cells may have been transduced with the AdBAI virus, and the tumors may have arisen from the cells not expressing BAI1. Alternatively, BAI1 expression levels may have decreased over AdBAI1-treatment prolongs the survival of mice inoculated intracerebrally with glioblastomas. The U87MG cell suspension was injected stereotactically to CD1 nu/nu athymic nude mice. After 3, 6, and 9 days, animals were administered with 5 Â 10 7 PFU AdBAI1 or AdMOCK (control). The mean survival time of AdBAI1-treated mice (2674.6 days) was significantly longer than that of AdMOCK-treated mice (17.372.3 days) (Po0.05).
time. Finally, although BAI1 clearly has antitumor and antiangiogenic effects, other proteins may be required for optimal activity in vivo. In support of this last possibility, decreased expression of fibroblast growth factor (FGF) binding protein, a secreted protein required for FGFmediated angiogenesis, was seen in squamous carcinoma cells both in vitro and in a xenograft mouse model after adenoviral vector-mediated wild-type p53 transduction. 17 In our study, differences in survival were seen within the AdBAI1 treated group. Analaysis of angiogenesis related gene expression by cDNA microarray in these tumors may reveal possible sources of heterogeneity in these tumors. 18 Taken together, our data clearly indicate that Ad-BAI1 is a potent candidate for gene therapy for the treatment of brain tumors, particularly human glioblastomas. Compared with current antiangiogenic treatments, namely the humanized monoclonal antibody targeting VEGF, 19 prolonged effects can be obtained using Ad-BAI1. Further studies with increased numbers of mice are clearly required before undertaking clinical trials, and the cellular response to BAI1 expression as well as any toxicity associated with AdBAI1 must be clarified. Perhaps the greatest promise lies in the combination of chemotherapy or radiation with BAI1 gene therapy.
